Skip to main content

$0.580 (0%)

High

$0.59

Low

$0.57

Trades

36

Turnover

$59,341

Volume

102,948
30 June 2023 at 3:56pm
Register to track NXS and receive email alerts.
Subject
NXS Ann: Oraderm Pharmaceuticals appointed as BlastX distributor

NXS Ann: Investor Presentation - Q1 2022

NXS Ann: Appendix 4C - 31 March 2022

NXS Ann: Quarterly Activity Report - 31 March 2022

NXS Ann: 2022 Corporate Governance Statement & Appendix 4G

NXS Ann: 2021 Annual Report

NXS Ann: Next Science 2022 AGM

NXS Ann: Appendix 3Y - Judith Mitchell

NXS Ann: Appendix 3Y - B Hancox

NXS Ann: Appendix 3Y - D Spira

NXS Ann: Appendix 3Y - M Compton

NXS Ann: Application for quotation of securities - NXS

NXS Ann: Notification of date of 2022 AGM

NXS Ann: Successful completion of Share Purchase Plan

NXS Ann: Next Science SPP Offer Opens

NXS Ann: Cleansing notice

NXS Ann: Application for quotation of securities - NXS

NXS Ann: Application for quotation of securities - NXS

NXS Ann: Investor briefing

NXS Ann: Proposed issue of securities - NXS

NXS Ann: Investor Presentation

NXS Ann: Next Science raises A$10M and launches A$5M SPP

NXS Ann: Investor Presentation

NXS Ann: Appendix 4E / FY21 Financial Statements

NXS Ann: Trading Halt

NXS Ann: Application for quotation of securities - NXS

NXS Ann: Notification of cessation of securities - NXS

NXS Ann: Notification of cessation of securities - NXS

NXS Ann: Investor Presentation - Q4 FY21

NXS Ann: Quarterly Activity Report - 31 December 2021

NXS Ann: Appendix 4C - 31 December 2021

NXS Ann: Enhanced sales & distribution relationship with Zimmer

NXS Ann: Jobkeeper Payments Notification

NXS Ann: XPERIENCE cleared by TGA for sale in Australia

NXS Ann: Q3 FY21 Investor Presentation

NXS Ann: Agreement signed with TELA Bio Inc

NXS Ann: Quarterly Activity Report & Appendix 4C - 30 September 2021

NXS Ann: Investor briefing

NXS Ann: Change in substantial holding

NXS Ann: Change in substantial holding

NXS Ann: Update on Irrimax complaint

NXS Ann: Managing Director's Address - Half Year Results

NXS Ann: Half Year Results Investor Presentation

NXS Ann: Half Year Results

NXS Ann: Half Year Report & Appendix 4D

NXS Ann: Irrimax complaint

NXS Ann: Half Year Results Investor Briefing

NXS Ann: Record revenue growth in 1H 2021

NXS Ann: Quarterly Activity Report - 30 June 2021

NXS Ann: Appendix 4C - 30 June 2021

Register to track NXS and receive email alerts.

Similar Companies

ANN
AVR
MGZ
NAN
OSX
PNV
SDI
SDI